CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.

1:17-cv-00227

Overview

Case Number 1:17-cv-00227
Filing Date 2017-03-03
Status Terminated
Termination Date 2019-03-18
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Novo Nordisk Inc. Operating Company

Represented By

3 Attorneys Listed

Brian P. Egan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9454

1201 North Market Street, P.O. Box 1347

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

5 Attorneys Listed

Thomas F. Fleming

Email: thomas.fleming@kirkland.com

Robert Hyberg

UNDELIVERABLE EMAIL 5/15/2019

Leora Ben-Ami

Email: leora.benami@kirkland.com

Gregory Springsted

Email: greg.springsted@kirkland.com

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Plaintiff

Novo Nordisk A/S NPE (Individual / Inventor)

Represented By

3 Attorneys Listed

Brian P. Egan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9454

1201 North Market Street, P.O. Box 1347

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 16 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 2 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (16): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (2 found):
PTAB: 2
USPTO PTAB Trial 2022-03-03
IPR2022-00657

Fresenius Kabi USA, LLC v. Novo Nordisk A/S

U.S. Continuation Sibling (8114833)
Status: Terminated-Settled
USPTO PTAB Trial 2020-07-22
IPR2020-01252

Pfizer Inc. v. Novo Nordisk A/S

U.S. Continuation Sibling (8114833)
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6268343
Derivatives of GLP-1 analogs
Filed: 1999-02-26
Issued: 2001-07-31
Expired (Term Ended) +1273d PTA
Expires: 2022-08-22
US9265893
Injection button
Filed: 2008-01-21
Issued: 2016-02-23
Active (5.8 yrs remaining) +1707d PTA
Expires: 2032-09-23
USRE41956
Dose setting limiter
Filed: 2005-05-04
Issued: 2010-11-23
Expired (Term Ended)
Expires: 2021-01-21
US8114833
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Filed: 2006-05-17
Issued: 2012-02-14
Expired (Term Ended) +118d PTA
Expires: 2026-09-12
US8846618
Stable formulation of modified GLP-1
Filed: 2010-05-24
Issued: 2014-09-30
Active (3.5 yrs remaining)
Expires: 2030-05-24

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1273 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

29

Dispositive

0

Granted

0

Denied

0

Pending / Review

18

Motions by Category

Procedural / Extension Motion 16 Claim Construction / Markman Filing 13

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED- re 81 STIPULATION TO EXTEND TIME to file redactions to the parties' Proposed Pretrial Order (D.I. 78-79) to February 25, 2019. Signed by Judge Sherr...
Entry #β€” • 2019-02-14
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to file redactions to the parties' Proposed Pretrial Order (D.I. 78-79) to February 25, 2019 - filed by Novo Nordisk A/S, Novo Nordis...
Entry #81 • 2019-02-13 Document →
Claim Construction / Markman Filing Pending / Under Review
REPORT AND RECOMMENDATIONS re: Claim Construction. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing cons...
Entry #61 • 2018-06-26 Document →
Procedural / Extension Motion Pending
SO ORDERED- re 57 STIPULATION TO EXTEND TIME for opening expert reports and rebuttal expert reports to July 13, 2018 and August 24, 2018, respectively. Signed b...
Entry #β€” • 2018-05-30
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for opening expert reports and rebuttal expert reports to July 13, 2018 and August 24, 2018, respectively - filed by Novo Nordisk A/S...
Entry #57 • 2018-05-25 Document →
Claim Construction / Markman Filing Pending
Markman Hearing
Entry #β€” • 2018-05-17

Docket Entries

(199 total)
Pleading / Complaint

COMPLAINT filed against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2097149.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit A-E, # 2 Civil Cover Sheet)(ceg) (Entered: 03/03/2017)

Entry #1 • 2017-03-03
1
Pleading / Complaint

COMPLAINT filed against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2097149.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit A-E, # 2 Civil Cover Sheet)(ceg) (Entered: 03/03/2017)

Entry #1 • 2017-03-03
2
Pleading / Complaint

COMPLAINT filed against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2097149.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit A-E, # 2 Civil Cover Sheet)(ceg) (Entered: 03/03/2017)

Entry #1 • 2017-03-03
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (ceg) (Entered: 03/03/2017)

Entry #2 • 2017-03-03
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/23/2017. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 7/23/2019. (ceg) (Entered: 03/03/2017)

Entry #3 • 2017-03-03
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc